NIKKEI 225
37,433.37 -646.33 (-1.70%) HANG SENG
16,385.87 +134.03 (+0.82%) CRUDE OIL
82.50 -0.23 (-0.28%) GOLD FUTURES
2,390.40 -7.60 (-0.32%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
50,825.61 +1,723.48 (+3.51%)
DBV Technologies S.A. (0QAJ.IL)
| Previous close | 1.2650 |
| Open | 0.0000 |
| Bid | 1.2260 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 3,016 |
| Market cap | 142.576M |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireInformation regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights03/31/2024 96,434,369 Total gross of voting rights: 96,434,369 Total net* of voting rights: 96,171,725 * Net total = total number of voting rights attached to shares – shares without voti
Insider MonkeyDBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript
DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript March 7, 2024 DBV Technologies S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results […]
Globe NewswireDBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K wi
